NORTH AMERICA IBS-C DRUG MARKET FORECAST 2017-2025
KEY FACTORS
The North American IBS-c drug market was valued at $439.5 million in 2016. The market is expected to grow at a CAGR of 7.30% and generate $825.07 million by 2025. The advanced medical and healthcare facility in the US and Canada, along with the continuous support from federal agencies and private medical firms are propelling the market in this region.
MARKET INSIGHTS
The market is segmented on the basis of the type of drug and type of prescription. The market segment by drug type is further divided into lubiprostone, linaclotide, stimulant laxatives, osmotic laxatives and pipeline drugs such as plecanatide. The market by prescription is divided into prescribed branded and generic drugs and over the counter drugs.
COMPETITIVE INSIGHTS
Some of the top players in the market include:
The North American IBS-c drug market was valued at $439.5 million in 2016. The market is expected to grow at a CAGR of 7.30% and generate $825.07 million by 2025. The advanced medical and healthcare facility in the US and Canada, along with the continuous support from federal agencies and private medical firms are propelling the market in this region.
MARKET INSIGHTS
The market is segmented on the basis of the type of drug and type of prescription. The market segment by drug type is further divided into lubiprostone, linaclotide, stimulant laxatives, osmotic laxatives and pipeline drugs such as plecanatide. The market by prescription is divided into prescribed branded and generic drugs and over the counter drugs.
COMPETITIVE INSIGHTS
Some of the top players in the market include:
- Catalent Pharmaceuticals Solutions
- Nestle
- Abbott Laboratories
- Synergy Pharmaceuticals
- Novartis Pharma
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
4.5.4. IBS CAN BE A HERITABILITY ISSUE
4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
4.6.1. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS
5. NORTH AMERICA IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. STIMULANT LAXATIVES
5.1.4. OSMOTIC LAXATIVES
5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)
6. NORTH AMERICA IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. NORTH AMERICA IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
8.1. US
8.2. CANADA
9. COMPANY PROFILES
9.1. CATALENT PHARMACEUTICALS SOLUTIONS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC MOVES
9.2. NESTLE
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
9.6.1. OVERVIEW
9.6.2. PRODUCTS PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. FERRING BV
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
9.20.1. OVERVIEW
9.20.2. PRODUCT PORTFOLIO
9.20.3. SCOT ANALYSIS
9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
9.21.1. OVERVIEW
9.21.2. PRODUCT PORTFOLIO
9.21.3. SCOT ANALYSIS
9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
9.22.1. OVERVIEW
9.22.2. PRODUCT PORTFOLIO
9.22.3. SCOT ANALYSIS
9.22.4. STRATEGIC MOVES
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
4.5.4. IBS CAN BE A HERITABILITY ISSUE
4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
4.6.1. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS
5. NORTH AMERICA IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. STIMULANT LAXATIVES
5.1.4. OSMOTIC LAXATIVES
5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)
6. NORTH AMERICA IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. NORTH AMERICA IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
8.1. US
8.2. CANADA
9. COMPANY PROFILES
9.1. CATALENT PHARMACEUTICALS SOLUTIONS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC MOVES
9.2. NESTLE
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
9.6.1. OVERVIEW
9.6.2. PRODUCTS PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. FERRING BV
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
9.20.1. OVERVIEW
9.20.2. PRODUCT PORTFOLIO
9.20.3. SCOT ANALYSIS
9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
9.21.1. OVERVIEW
9.21.2. PRODUCT PORTFOLIO
9.21.3. SCOT ANALYSIS
9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
9.22.1. OVERVIEW
9.22.2. PRODUCT PORTFOLIO
9.22.3. SCOT ANALYSIS
9.22.4. STRATEGIC MOVES
LIST OF TABLES
TABLE 1 NORTH AMERICA IBS-C MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 NORTH AMERICA IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 5 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 6 PRODUCT PROFILE (LINACLOTIDE)
TABLE 7 PRODUCT PROFILE (BISACODYL)
TABLE 8 PRODUCT PROFILE (SENNA)
TABLE 9 PRODUCT PROFILE (LACTULOSE)
TABLE 10 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 11 PRODUCT PROFILE (PSYLLIUM)
TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 13 NORTH AMERICA IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 16 PRODUCT PROFILE (METAMUCIL)
TABLE 17 NORTH AMERICA IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 1 NORTH AMERICA IBS-C MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 NORTH AMERICA IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 5 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 6 PRODUCT PROFILE (LINACLOTIDE)
TABLE 7 PRODUCT PROFILE (BISACODYL)
TABLE 8 PRODUCT PROFILE (SENNA)
TABLE 9 PRODUCT PROFILE (LACTULOSE)
TABLE 10 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 11 PRODUCT PROFILE (PSYLLIUM)
TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 13 NORTH AMERICA IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 16 PRODUCT PROFILE (METAMUCIL)
TABLE 17 NORTH AMERICA IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 NORTH AMERICA IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 NORTH AMERICA IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 5 DIETS RESPONSIBLE FOR IBS
FIGURE 6 PERCENTAGE OF PERSONS AGED 12 AND OVER WITH DEPRESSION BY AGE AND SEX US, 2009-2012
FIGURE 7 DRUGS PULLED OFF FROM THE MARKET
FIGURE 8 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 9 US IBS-C DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 CANADA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 1 NORTH AMERICA IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 NORTH AMERICA IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 NORTH AMERICA IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 5 DIETS RESPONSIBLE FOR IBS
FIGURE 6 PERCENTAGE OF PERSONS AGED 12 AND OVER WITH DEPRESSION BY AGE AND SEX US, 2009-2012
FIGURE 7 DRUGS PULLED OFF FROM THE MARKET
FIGURE 8 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 9 US IBS-C DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 CANADA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
